Onivyde (irinotecan)

drip
100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card
Enquire now
We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Onivyde (irinotecan)

How to buy Onivyde:  You can order Onivyde (irinotecan liposome) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Baxalta Innovations GmbHMerrimack Pharmaceuticals Inc.
Disease Pancreatic Cancer
Indication Pancreatic Neoplasms
Mode of Action Topoisomerase inhibitor
Approval Status EMA approved (EU); FDA approved (USA); TGA approved (AUS)
CAS Number 97682-44-5
Strength 5 mg/mL, 4.3 mg/mL

Who is irinotecan injection for?

Onivyde (irinotecan) is indicated in combination with 5-fluorouracil and leucovorin (two other cancer medicines [6][7]) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy [1][2][5].

The EMA approved Onivyde marketed by Baxalta Innovations GmbH contains 5 mg irinotecan hydrochloride trihydrate per 1 mL, this corresponds to the FDA and TGA approved Onivyde marketed by Merrimack Pharmaceuticals Inc. and containing 4.3 mg irinotecan in 1 mL [3].

Recommended dose

Complete information about Onivyde (irinotecan) dosage and administration can be found here [2][3]. Note that the EMA approved Onivyde marketed by Baxalta Innovations GmbH contains the equivalent of 5 mg irinotecan hydrochloride trihydrate (as irinotecan sucrosofate salt in a pegylated liposomal formulation) which corresponds to 4.3 mg/1 mL irinotecan [3]. The latter is the strength approved by the FDA and TGA [2][5].

The standard EMA dosage (Onivyde (irinotecan) 5 mg/mL) is:
  • 80 mg/m2 administered by intravenous infusion every 2 weeks followed by 5‑fluorouracil and leucovorin[3].
The standard FDA and TGA dosage (Onivyde (irinotecan) 4.3 mg/mL) is:
  • 70 mg/m2 administered by intravenous infusion every 2 weeks followed by 5‑fluorouracil and leucovorin [2][5].

What is irinotecan and how does it work?

Onivyde (irinotecan) is a cancer medicine used to treat adults with metastatic adenocarcinoma of the pancreas. It is used together with 5-fluorouracil and leucovorin (two other cancer medicines) in adults whose cancer has worsened despite treatment containing the cancer medicine gemcitabine [1][2].The active substance in Onivyde, irinotecan, is a topoisomerase inhibitor. It blocks an enzyme called topoisomerase I. This enzyme is involved in copying cell DNA, which is needed to make new cells. By blocking the enzyme, cancer cells are prevented from multiplying and they eventually die. In Onivyde, irinotecan is contained within tiny fat particles called ‘liposomes’. The liposomes are expected to accumulate within the tumour and release the medicine slowly over time, thereby allowing it to act for longer [1].

What is irinotecan's approval status?


Onivyde (irinotecan) was approved by:
  • FDA (USA) on October 22, 2015 [4]
  • EMA (EU) on October 14, 2016 [1]
  • TGA (AUS) on December 19, 2016 [5]
for metastatic adenocarcinoma of the pancreas for use in combination with 5-fluorouracil and leucovorin in adults whose cancer has gotten worse despite treatment containing the cancer medicine gemcitabine.

The approvals were based on a study (NAPOLI–1 [8]) involving a total of 417 adults with metastatic adenocarcinoma of the pancreas whose cancer worsened despite cancer treatment that contained gemcitabine. Patients were given Onivyde or 5-fluorouracil plus leucovorin, or the three medicines in combination. The main measure of effectiveness was that the addition of Onivyde to the 5-fluorouracil plus leucovorin regimen prolonged patients’ lives. Patients taking the three medicines together lived for around 6.1 months (95 % CI: 4.8, 8.5), compared with 4.2 months(95 % CI: 3.3, 5.3) for patients taking 5-fluorouracil plus leucovorin [4][5], and 4.9 months for patients taking Onivyde alone [1]

The most common side effects with Onivyde are diarrhoea, nausea, vomiting, loss of appetite, neutropenia (low levels of neutrophils, a type of white blood cell), tiredness, weakness, anaemia (low red blood cell counts) stomatitis (inflammation of the lining of the mouth) and fever [1].
References
[1] EMA. Human Medicines: Onivyde (irinotecan hydrochloride trihydrate), 25/10/2016, cited on 18/01/2017.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004125/human_med_002022.jsp&mid=WC0b01ac058001d124
[2] Summary of Product Characteristics [FDA]: Onivyde (irinotecan liposome injection), Merrimack Pharmaceuticals Inc., Oct. 2015.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207793lbl.pdf
[3] Summary of Product Characteristics [EMA]: Onivyde (liposomal irinotecan), Baxalta Innovations GmbH, Oct. 2016.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004125/WC500215029.pdf
[4] FDA News Release: FDA approves new treatment for advanced pancreatic cancer, 22/10/2015.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468654.htm
[5] Summary of Product Characteristics [TGA]: Onivyde (liposomal irinotecan), Baxalta Australia Pty Ltd, Dec. 2016.
https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2016-PI-02871-1&d=2017102716114622483
[6] Wikipedia. Fluorouracil. (last update: 5/11/2017), cited on 18/01/2017.
https://en.wikipedia.org/wiki/Fluorouracil
[7] Wikipedia. Folinic acid. (last update: 11/09/2017), cited on 18/01/2017.
https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=1205B876CA4F377DCA257C99003CA376&agid=(PrintDetailsPublic)&actionid=1
[8] Wang-Gillam A., et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. The Lancet. 2016 Feb 6; 387(10018):545–557.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2900986-1/abstract









"TheSocialMedwork helped us to get the medicine, which was not accessible for us, in the shortest possible time."

- Haoyu, China.
Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.



Share our website

Follow us


DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision. Privacy Policy / Terms and Conditions
Our service uses cookies.